Management of Patients Undergoing Percutaneous Coronary Revascularization

Annals of Internal Medicine

Volumn 139, Issue 2, 2003, Pages

  Levine, Glenn N ^a   Kern, Morton J ^b   Berger, Peter B ^b   Brown, David L ^b   Klein, Lloyd W ^b   Kereiakes, Dean J ^b   Sanborn, Timothy A ^b   Jacobs, Alice K ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CIMETIDINE; CLOPIDOGREL; DIPHENHYDRAMINE; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IODINATED CONTRAST MEDIUM; IODIXANOL; METFORMIN; PACLITAXEL; PREDNISONE; RAPAMYCIN; STEROID; THIENO[2,3 B]PYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; WARFARIN; CONTRAST MEDIUM;

ABDOMINAL PAIN; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; BLEEDING; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DEVICE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; EMERGENCY SURGERY; FALSE ANEURYSM; FLANK PAIN; FLUID THERAPY; HEART INFARCTION; HEMATOCRIT; HEMATOMA; HUMAN; HYPOTENSION; IMAGING; INGUINAL HEMATOMA; INGUINAL PAIN; INGUINAL REGION; ISCHEMIA; KIDNEY DISEASE; LACTIC ACIDOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATIENT CARE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; RETROPERITONEAL HEMATOMA; REVIEW; STENT THROMBOSIS; THROMBOCYTOPENIA; THROMBOSIS; VASCULAR CLOSURE DEVICE; VASCULAR DISEASE; CORONARY ARTERY OBSTRUCTION; METHODOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CONTRAST MEDIA; CORONARY STENOSIS; HUMANS; PATIENT CARE TEAM;

EID: 0041802730     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-2-200307150-00012     Document Type: Review

References (180)

1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61-8. [PMID: 449946]
2. Greenberger PA, Patterson R. Adverse reactions to radiocontrast media. Prog Cardiovasc Dis. 1988;31:239-48. [PMID: 3055068]
3. Goss JE, Chambers CE, Heupler FA Jr. Systemic anaphylactoid reactions to iodinated contrast media during cardiac catheterization procedures: guidelines for prevention, diagnosis, and treatment. Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn. 1995;34:99-104; discussion 105. [PMID: 7788704]
4. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999;33:1756-824. [PMID: 10334456]
5. Johnson LW, Lozner EC, Johnson S, Krone R, Pichard AD, Vetrovec GW, et al. Coronary arteriography 1984-1987: a report of the Registry of the Society for Cardiac Angiography and Interventions. I. Results and complications. Cathet Cardiovasc Diagn. 1989;17:5-10. [PMID: 2720767]
6. Lasser EC, Berry CC, Talner LB, Santini LC, Lang EK, Gerber FH, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med. 1987;317:845-9. [PMID: 3627208]
7. Greenberger PA, Patterson R, Tapio CM. Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of beta-adrenergic antagonists. Arch Intern Med. 1985;145:2197-200. [PMID: 2866755]
8. Lieberman P, Siegle RL, Treadwell G. Radiocontrast reactions. Clin Rev Allergy. 1986;4:229-45. [PMID: 2870792]
9. Shehadi WH. Adverse reactions to intravascularly administered contrast media. A comprehensive study based on a prospective survey. Am J Roentgenol Radium Ther Nucl Med. 1975;124:145-52. [PMID: 1170768]
10. Lang DM, Alpem MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med. 1991;115:270-6. [PMID: 1677239]
11. Hildreth EA. Anaphylactoid reactions to iodinated contrast media. Hosp Pract (Off Ed). 1987;22:77-85, 89-90, 95. [PMID: 3108279]
12. Wittbrodt ET, Spinler SA. Prevention of anaphylactoid reactions in high-risk patients receiving radiographic contrast media. Ann Pharmacother. 1994;28:236-41. [PMID: 8173143]
13. Kern MJ, Roth R. Introduction to the catheterization laboratory. In: Kern MJ. The Cardiac Catheterization Handbook. 4th ed. St. Louis: Mosby; 2003:1-51.
14. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000;11:177-82. [PMID: 10616853]
15. Porter GA. Contrast-associated nephropathy. Am J Cardiol. 1989;64:22E-26E. [PMID: 2672765]
16. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-9. [PMID: 12571256]
17. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40:298-303. [PMID: 12106935]
18. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143:894-903. [PMID: 12040355]
19. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383-8. [PMID: 12392825]
20. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-20. [PMID: 79692801
21. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol. 1999;33:403-11. [PMID: 9973020]
22. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-75. [PMID: 9375704]
23. Vlietstra RE, Nunn CM, Narvarte J, Browne KF. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J. 1996;132:1049-50. [PMID: 8892783]
24. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 1992;62:413-5. [PMID: 1300436]
25. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990;89:615-20. [PMID: 2239981]
26. Lip GY, Rathore VS, Katira R, Singh SP, Watson RD. Changes in renal function with percutaneous transluminal coronary angioplasty. Int J Cardiol. 1999;70:127-31. [PMID: 10454300]
27. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-8. [PMID: 11079656]
28. Eisenberg RL, Bank WO, Hedgcock MW. Renal failure after major angiography. Am J Med. 1980;68:43-6. [PMID: 7350804]
29. Brown RS, Ransil B, Clark BA. Prehydration protects against contrast nephropathy in high risk patients undergoing cardiac catheterization [Abstract]. J Am Soc Nephrol. 1990;1:330A.
30. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45:259-65. [PMID: 8127017]
31. Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83:260-3, A5. [PMID: 10073832]
32. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31:674-80. [PMID: 9531185]
33. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high-and low-osmolarity iodinated contrast media. Radiology. 1993;188:171-8. [PMID: 8511292]
34. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-4. [PMID: 10900277]
35. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002;89:356-8. [PMID: 11809444]
36. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002;57:279-83. [PMID: 12410497]
37. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289:553-8. [PMID: 12578487]
38. Heupler FA Jr. Guidelines for performing angiography in patients taking metformin. Members of the Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn. 1998;43:121-3. [PMID: 9488538]
39. Nawaz S, Cleveland T, Gaines PA, Chan P. Clinical risk associated with contrast angiography in merformin treated patients: a clinical review. Clin Radiol. 1998;53:342-4. [PMID: 9630271]
40. Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR. Metformin-induced lactic acidosis in the presence of acute renal failure. Diabetologia. 1977;13:211-7. [PMID: 406158]
41. McCartney MM, Gilbert FJ, Murchison LE, Pearson D, McHardy K, Murray AD. Metformin and contrast media - a dangerous combination? Clin Radiol. 1999;54:29-33. [PMID: 9915507]
42. Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomson PDR; 2003:1079-85.
43. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty N Engl J Med. 1988;318:1714-9. [PMID: 2967433]
44. White CW, Chaitman B, Lassar TA, Marcus ML, Chisholm RJ, Knudson M, et al. Antiplatelet agents are effective in reducing the immediate complications of PTCA: results from the ticlopidine multicenter trial [Abstract]. Circulation. 1987;76(Suppl IV):IV400.
45. Bertrand ME, Allain H, Lablanche JM. Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty [Abstract]. The TACT study. Circulation. 1990;82(Suppl III):III-90.
46. Chesebro JH, Webster MW, Lassar TA. Coronary angioplasty: antiplatelet therapy reduces acute complications but not restenosis [Abstract]. Circulation. 1989;80(Suppl II):II-64.
47. Lembo NJ, Black AJ, Roubin GS, Wilentz JR, Mufson LH, Douglas JS Jr, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol. 1990;65:422-6. [PMID: 2407084]
48. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001;37:2215-39. [PMID: 11419905]
49. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667-72. [PMID: 10517740]
50. Steinhubl SR, Lauer MS, Mukherjee DP, Moliterno DJ, Lincoff AM, Ellis SG, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol. 1998;32:1366-70. [PMID: 9809949]
51. Steinhubl SR, Ellis SG, Wolski K, Lincoff AM, Topol EJ. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation. 2001;103:1403-9. [PMID: 11245644]
52. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-94. [PMID: 11419425]
53. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet. 2001;358:527-33. [PMID: 11520521]
54. Berger PB, Steinhubl S. Clinical implications of percutaneous coronary intervention-clopiclogrel in unstable angina to prevent recurrent events (PCICURE) study: a US perspective. Circulation. 2002;106:2284-7. [PMID: 12390961]
55. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20. [PMID: 12435254]
56. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. [PMID: 11519503]
57. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231-7. [PMID: 12106925]
58. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349:1429-35. [PMID: 9164316]
59. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med. 1997;336:1689-96. [PMID: 9182212]
60. Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998;352:87-92. [PMID: 9672272]
61. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-44. [PMID: 11145489]
62. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998;339:436-43. [PMID: 9705684]
63. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998;338:1488-97. [PMID: 9599103]
64. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-74. [PMID: 12383588]
65. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991;17:621-6. [PMID: 1993778]
66. Kini A, Kini S, Marmur JD, Bertea T, Dangas G, Cocke TP, et al. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv. 1999;48:123-9. [PMID: 10506764]
67. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-69. [PMID: 10987628]
68. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-51. [PMID: 9462562]
69. Klein LW. Significance of creatine kinase release after coronary interventions [Editorial]. Catheter Cardiovasc Interv. 1999;48:130-2. [PMID: 10506765]
70. Baim DS, Cutlip DE, Midei M, Linnemeier TJ, Schreiber T, Cox D, et al. Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001;87:157-62. [PMID: 11152831]
71. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-9. [PMID: 11717596]
72. Harrington RA, Lincoff AM, Califf RM, Holmes DR Jr, Berdan LG, O'Hanesian MA, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol. 1995;25:1693-9. [PMID: 7759725]
73. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopiclogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624-9. [PMID: 10931801]
74. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994;330:956-61. [PMID: 8121459]
75. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422-8. [PMID: 9164315]
76. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-63. [PMID: 12588269]
77. Effecrs of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. 1997;96:1445-53. [PMID: 9315530]
78. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-71. [PMID: 9834303]
79. Bhalla HS, Topol EJ. Non Q MI post percutaneous coronary revascularization is underreported unless there is systemic collection of enzymatic data [Abstract]. Circulation. 1996;94(Suppl I):I-51.
80. King SB 3rd, Yeh W, Holubkov R, Baim DS, Sopko G, Desvigne-Nickens P, et al. Balloon angioplasty versus new device intervention: clinical outcomes. A comparison of the NHLBI PTCA and NACI registries. J Am Coll Cardiol. 1998;31:558-66. [PMID: 9502635]
81. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA. 1997;278:479-84. [PMID: 9256222]
82. Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ. Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation. 1995;91:2733-41. [PMID: 7758178]
83. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996;131:1097-105. [PMID: 8644587]
84. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528-36. [PMID: 8840840]
85. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277:461-6. [PMID: 9020269]
86. Simoons ML, Harrington R, Lincoff M, Anderson K, Deckers JW, Boersma E, et al. Impaired prognosis after small, non-Q myocardial infarction during PTCA [Abstract]. Eur Heart J. 1997;18(Suppl):132.
87. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation. 2001;104:642-7. [PMID: 11489768]
88. Shah PB, Holper E, Hughes MD, Kunt RE. Asymptomatic CK-MB elevation after PCI is not correlated with late mortality [Abstract]. Circulation 2001;104(Suppl II):II-706.
89. Ellis SG, Schneider JP, Brener SJ, Topol EJ. Key factors associated with late death after non-Q wave MI with PCI-timing, LV function, extent of revascularization, non-use of statins or antiinflammatory medications [Abstract]. Circulation. 2001;104(Suppl II):II-706.
90. Kanaparti PK, Brown DL. Relation between coronary atherosclerotic plaque burden and cardiac enzyme elevation following percutaneous coronary intervention. Am J Cardiol. 2000;86:619-22. [PMID: 10980211]
91. Ohman EM, Tardiff BE. Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. Importance and implications [Editorial]. JAMA. 1997;277:495-7. [PMID: 9020275]
92. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol. 2000;35:1103-15. [PMID: 10758948]
93. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001;119:32IS-336S. [PMID: 11157657]
94. Garachemani AR, Kaufmann U, Fleisch M, Meier B. Prolonged heparin after uncomplicated coronary interventions: a prospective, randomized trial. Am Heart J. 1998;136:352-6. [PMID: 9704701]
95. Kong DF, Califf RM. Post-procedure heparin: boon or burden? [Editorial] Am Heart J. 1998;136:183-5. [PMID: 9704676]
96. Waksman R, King SB 3rd, Douglas JS, Shen Y, Ewing H, Mueller L, et al. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol. 1995;75:886-9. [PMID: 7732995]
97. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol. 1998;81:36-40. [PMID: 9462603]
98. Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol. 1997;79:286-91. [PMID: 9036746]
99. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB 3rd. Effect of 18-to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 1989;117:777-82. [PMID: 2522716]
100. Friedman HZ, Cragg DR, Glazier SM, Gangadharan V, Marsalese DL, Schreiber TL, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol. 1994;24:1214-9. [PMID: 7930242]
101. Shubrooks SJ Jr, Nesto RW, Leeman D, Waxman S, Lewis SM, Fitzpatrick P, et al. Utgent cotonary bypass surgery for failed percutaneous coronary intervention in the stent era: Is backup still necessary? Am Heart J. 2001;142:190-6. [PMID: 11431677]
102. Angelini P, Vaughn WK, Zaqqa M, Wilson JM, Fish RD. Impact of the "stent-when-feasible" policy on in-hospital and 6-month success and complication rates after coronary angioplasty: single-center experience with 17,956 revascularization procedures (1993-1997). Tex Heart Inst J. 2000;27:337-45. [PMID: 11198305]
103. Hasdai D, Berger PB, Bell MR, Rihal CS, Garratt KN, Holmes DR Jr. The changing face of coronary interventional practice. The Mayo Clinic experience. Arch Intern Med. 1997;157:677-82. [PMID: 9080922]
104. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 2000;102:2945-51. [PMID: 11113044]
105. Altmann DB, Racz M, Battleman DS, Bergman G, Spokojny A, Hannan EL, et al. Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients. Am Heart J. 1996;132:503-7. [PMID: 8800018]
106. McGrath PD, Malenka DJ, Wennberg DE, Shubrooks SJ Jr, Bradley WA, Robb JF, et al. Changing outcomes in percutaneous coronary interventions: a study of 34,752 procedures in northern New England, 1990 to 1997. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol. 1999;34:674-80. [PMID: 10483947]
107. Loubeyre C, Morice MC, Berzin B, Virot P, Commeau P, Drobinski G, et al. Emergency coronary artery bypass surgery following coronary angioplasty and stenting: results of a French multicenter registry. Catheter Cardiovasc Interv. 1999;47:441-8. [PMID: 10470474]
108. Laskey WK, Kimmel S, Krone RJ. Contemporary trends in coronary intervention: a report from the Registry of the Society for Cardiac Angiography and Interventions. Catheter Cardiovasc Interv. 2000;49:19-22. [PMID: 10627359]
109. Rankin JM, Spinelli JJ, Carere RG, Ricci DR, Penn IM, Hilton JD, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med. 1999;341:1957-65. [PMID: 10607812]
110. Laskey WK, Williams DO, Vlachos HA, Cohen H, Holmes DR, King SB 3rd, et al. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry. Am J Cardiol. 2001;87:964-9; A3-4. [PMID: 11305987]
111. Nasser TK, Mohler ER 3rd, Wilensky RL, Hathaway DR. Peripheral vascular complications following coronary interventional procedures. Clin Cardiol. 1995;18:609-14. [PMID: 8590528]
112. Kent KC, Moscucci M, Mansour KA, DiMattia S, Gallagher S, Kuntz R, et al. Retroperitoneal hematoma after cardiac catheterization: prevalence, risk factors, and optimal management. J Vasc Surg. 1994;20:905-10; discussion 910-3. [PMID: 7990185]
113. Sreeram S, Lumsden AB, Miller JS, Salam AA, Dodson TF, Smith RB. Retroperitoneal hematoma following femoral arterial catheterization: a serious and often fatal complication. Am Surg. 1993;59:94-8. [PMID: 8476149]
114. Kranjec I, Cerne A. Vascular complications after percutaneous coronary interventions using abciximab (Reopro): prospective evaluation with Doppler color flow imaging. J Invasive Cardiol. 2000;12:86-94. [PMID: 10731270]
115. Katzenschlager R, Ugurluoglu A, Ahmadi A, Hulsmann M, Koppensteiner R, Larch E, et al. Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. Radiology. 1995;195:463-6. [PMID: 7724767]
116. Samal AK, White CJ. Percutaneous management of access site complications. Catheter Cardiovasc Interv. 2002;57:12-23. [PMID: 12203921]
117. Wiley JM, White CJ, Uretsky BF. Noncoronary complications of coronary intervention. Catheter Cardiovasc Interv. 2002;57:257-65. [PMID: 12357533]
118. Moscucci M, Mansour KA, Kent KC, Kuntz RE, Senerchia C, Baim DS, et al. Peripheral vascular complications of directional coronary atherectomy and stenting: predictors, management, and outcome. Am J Cardiol. 1994;74:448-53. [PMID: 8059724]
119. Akkerhuis KM, Deckers JW, Lincoff AM, Tcheng JE, Boersma E, Anderson K, et al. Risk of stroke associated with abciximab among patients undergoing petcutaneous coronary intervention. JAMA. 2001;286:78-82. [PMID: 11434830]
120. Fuchs S, Stabile E, Kinnaird TD, Mintz GS, Gruberg L, Canos DA, et al. Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications. Circulation. 2002;106:86-91. [PMID: 12093775]
121. Weintraub WS, Mahoney EM, Ghazzal ZM, King SB 3rd, Culler SD, Morris DC, et al. Trends in outcome and costs of coronary intervention in the 1990s. Am J Cardiol. 2001;88:497-503. [PMID: 11524057]
122. Brown DL, Topol EJ. Stroke complicating percutaneous coronary tevascularization. Am J Cardiol. 1993;72:1207-9. [PMID: 8237818]
123. Toursarkissian B, Mejia A, Smilanich RP, Shireman PK, Sykes MT. Changing patterns of access site complications with the use of percutaneous closure devices. Vasc Surg. 2001;35:203-6. [PMID: 11452346]
124. Dangas G, Mehran R, Kokolis S, Feldman D, Sader LF, Pichard AD, et al. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol. 2001;38:638-41. [PMID: 11527609]
125. Carere RG, Webb JG, Miyagishima R, Djurdev O, Ahmed T, Dodek A. Groin complications associated with collagen plug closure of femoral arterial puncture sites in anticoagulated patients. Cathet Cardiovasc Diagn. 1998;43:124-9. [PMID: 9488539]
126. Camenzind E, Grossholz M, Urban P, Dorsaz PA, Didier D, Meier B. Collagen application versus manual compression: a prospective randomized trial for arterial puncture site closure after coronary angioplasty. J Am Coll Cardiol. 1994;24:655-62. [PMID: 8077535]
127. Fram DB, Giri S, Jamil G, Mitchel JF, Boden WE, Din S, et al. Suture closure of the femoral arteriotomy following invasive cardiac procedures: a detailed analysis of efficacy, complications, and the impact of early ambulation in 1,200 consecutive, unselected cases. Catheter Cardiovasc Interv. 2001;53:163-73. [PMID: 11387599]
128. Sanborn TA, Gibbs HH, Brinker JA, Knopf WD, Kosinski EJ, Roubin GS. A multicenter randomized trial comparing a percutaneous collagen hemostasis device with conventional manual compression after diagnostic angiography and angioplasty. J Am Coll Cardiol. 1993;22:1273-9. [PMID: 8227779]
129. Baim DS, Knopf WD, Hinohara T, Schwarten DE, Schatz RA, Pinkerton CA, et al. Suture-mediated closure of the femoral access site after cardiac catheterization: results of the suture to ambulate and discharge (STAND I and STAND II) trials. Am J Cardiol. 2000;85:864-9. [PMID: 10758928]
130. Eidt JF, Habibipour S, Saucedo JF, McKee J, Southern F, Barone GW, et al. Surgical complications from hemostatic puncture closure devices. Am J Surg. 1999;178:511-6. [PMID: 10670863]
131. Carere RG, Webb JG, Buller CE, Wilson M, Rahman T, Spinelli J, et al. Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge. Am Heart J. 2000;139:52-8. [PMID: 10618562]
132. Kussmaul WG 3rd, Buchbinder M, Whidow PL, Aker UT, Heuser RR, King SB, et al. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995;25:1685-92. [PMID: 7759724]
133. Resnic FS, Blake GJ, Ohno-Machado L, Selwyn AP, Popma JJ, Rogers C. Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors. Am J Cardiol. 2001;88:493-6. [PMID: 11524056]
134. Sprouse LR 2nd, Botta DM Jr, Hamilton IN Jr. The management of peripheral vascular complications associated with the use of percutaneous suture-mediated closure devices. J Vasc Surg. 2001;33:688-93. [PMID: 11296318]
135. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-71. [PMID: 11306525]
136. Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6-12. [PMID: 8996288]
137. Karrillon GJ, Morice MC, Benveniste E, Bunouf P, Aubry P, Cattan S, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation. 1996;94:1519-27. [PMID: 8840839]
138. Schuhlen H, Kastrati A, Pache J, Dirschinger J, Schomig A. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol. 2001;37:2066-73. [PMID: 11419889]
139. Albiero R, Hall P, Itoh A, Blengino S, Nakamura S, Martini G, et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation. 1997;95:1145-56. [PMID: 9054843]
140. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-9. [PMID: 8598866]
141. Dangas G, Mehran R, Abizaid AS, Curry BH, Lansky AJ, Kent KM, et al. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol. 2001;87:470-2, A7. [PMID: 1179539]
142. Wilson SH, Rihal CS, Bell MR, Velianou JL, Holmes DR Jr, Berger PB. Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am J Cardiol. 1999;83:1006-11. [PMID: 10190510]
143. Stables RH. Clopidogrel in invasive management of non-ST-elevation ACS. Lancet. 2001;358:520-1. [PMID: 11520515]
144. Dieter RS. Coronary artery stent infection. Clin Cardiol. 2000;23:808-10. [PMID: 11097126]
145. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA. 1997;277:1794-801. [PMID: 9178793]
146. Shellock FG. Guide to MR Procedures and Metallic Objects: Update 1999. 5th ed. Philadelphia: Lippincott Williams & Wilkins Health; 1999.
147. Shellock FG. MRI safety. Accessed at MRIsafety.com on 26 June 2001.
148. Jost C, Kumar VV. Are Current Cardiovascular Stents MRI Safe? J Invasive Cardiol. 1998;10:477-479. [PMID: 10762825]
149. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35-43. [PMID: 8964115]
150. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol. 1993;21:15-25. [PMID: 8417056]
151. Levine GN, Chodos AP, Loscalzo J. Restenosis following coronary angioplasty: clinical presentations and therapeutic options. Clin Cardiol. 1995;18:693-703. [PMID: 8608668]
152. Miller JM, Ohman EM, Moliterno DJ, Califf RM. Restenosis: the clinical issues. In: Topol EJ, ed. Textbook of Interventional Cardiology. 3rd ed. Philadelphia: WB Saunders; 1999:379-415.
153. Rensing BJ, Hermans WR, Vos J, Tijssen JG, Rutch W, Danchin N, et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation. 1993;88:975-85. [PMID: 8353925]
154. Weintraub WS, Kosinski AS, Brown CL 3rd, King SB 3rd. Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol. 1993;21:6-14. [PMID: 8417077]
155. Holmes DR Jr, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984;53:77C-81C. [PMID: 6233894]
156. Califf RM, Fortin DF, Frid DJ, Harlan WR 3rd, Ohman EM, Bengtson JR, et al. Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol. 1991;17:2B-13B. [PMID: 2016478]
157. Hirshfeld JW Jr, Schwartz JS, Jugo R, MacDonald RG, Goldberg S, Savage MP, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. J Am Coll Cardiol. 1991;18:647-56. [PMID: 1869725]
158. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361-71. [PMID: 2962786]
159. Joelson JM, Most AS, Williams DO. Angiographic findings when chest pain recurs after successful percutaneous transluminal coronary angioplasty. Am J Cardiol. 1987;60:792-5. [PMID: 2959139]
160. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA. 2000;284:1828-36. [PMID: 11025836]
161. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999;341:1949-56. [PMID: 10607811]
162. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med. 1997;337:740-7. [PMID: 9287229]
163. Hanekamp CC, Koolen JJ, Den Heyer P, Schalij MJ, Piek JJ. A randomized comparison between balloon angioplasty and elective stent implantation in venous bypass grafts: the Venestent study [Abstract]. J Am Coll Cardiol. 2000;35(Suppl A):9A.
164. Buller CE, Dzavik V, Carere RG, Mancini GB, Barbeau G, Lazzam C, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation. 1999;100:236-42. [PMID: 10411846]
165. Hoher M, Wohrle J, Grebe OC, Kochs M, Osterhues HH, Hombach V, et al. A randomized trial of elective stenting after balloon recanalization of chronic total occlusions. J Am Coll Cardiol. 1999;34:722-9. [PMID: 10483953]
166. Sirnes PA, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P, et al. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996;28:1444-51. [PMID: 8917256]
167. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-11. [PMID: 11673337]
168. Grube E, Silber SM, Hauptmann KE. Taxus I: prospective, randomized, double-blind comparison of NIRx stents coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls [Abstract]. Circulation. 2001;104(Suppl II):II-463.
169. Gershlick AH, Descheerder I, Chevalier B, Camenzind E, Gummeaux A, Vrints C, et al. Local drug delivery to inhibit coronary artery restenosis: data from the ELUTES (Evaluation of paclitaxel eluting stent) clinical trial [Abstract]. Circulation. 2001;104 (Suppl II):II-416.
170. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-45. [PMID: 12700373]
171. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80. [PMID: 12050336]
172. Grube E, Hauptmann K, Colombo A, DiSciascio G, Silber S, Bach S, et al. SCORE trial interim safety results: despite efficacy, late scent thrombosis with the QuaDDS-QP2 scent [Abstract]. J Am Coll Cardiol. 2002;39:38A.
173. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol. 1997;30:260-311. [PMID: 9207652]
174. Garzon P, Eisenberg MJ. Functional testing for the detection of restenosis after percutaneous cransluminal coronary angioplasty: a meta-analysis. Can J Cardiol. 2001;17:41-8. [PMID: 11173313]
175. Hernandez RA, Macaya C, Iniguez A, Alfonso F, Goicolea J, Fernandez-Ortiz A, et al. Midterm outcome of patients with asymptomatic restenosis after coronary balloon angioplasty. J Am Coll Cardiol. 1992;19:1402-9. [PMID: 1593031]
176. Chenu PC, Schroeder E, Kremer R, Marchandise B. Long-term outcome of patients with asymptomatic restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1993;72:1209-11. [PMID: 8237819]
177. Laarman G, Luijten HE, van Zeyl LG, Beatt KJ, Tijssen JG, Serruys PW, et al. Assessment of "silent" restenosis and long-term follow-up after successful angioplasty in single vessel coronary artery disease: the value of quantitative exercise electrocardiography and quantitative coronary angiography. J Am Coll Cardiol. 1990;16:578-85. [PMID: 2101583]
178. Kovac JD, Brack MJ, Harley A, Gershlick AH. Longer term clinical outcome in patients presenting with asymptomatic restenosis at 4 month trial angiography [Abstract]. Circulation. 1995;92(Suppl):1-347.
179. Krone RJ, Hardison RM, Chaitman BR, Gibbons RJ, Sopko G, Bach R, et al. Risk stratification after successful coronary revascularization: the lack of a role for routine exercise testing. J Am Coll Cardiol. 2001;38:136-42. [PMID: 11451263]
180. Ritchie JL, Bateman TM, Bonow RO, Crawford MH, Gibbons RJ, Hall RJ, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol. 1995;25:521-47. [PMID: 7829809]